Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: A post-hoc analysis from ARTEMIS-UC

被引：0
|
作者：
Peyrin-Biroulet, L. [1 ]
Yen, M. [2 ]
Zhou, W. [2 ]
Dong, B. [2 ]
Danese, S. [3 ]
Feagan, B. G. [4 ,5 ]
Sands, B. E. [6 ]
机构：
[1] CHRU Nancy, INFINY Inst, Dept Gastroenterol, INSERM,NGERE, Nancy, France
[2] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA
[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Gastroenterol & Gastrointestinal Endoscopy Unit, Milan, Italy
[4] Western Univ, Dept Med Epidemiol, London, ON, Canada
[5] Western Univ, Dept Biostat, London, ON, Canada
[6] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1259
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1085
引用
收藏
页码：i1997 / i1998
页数：2
相关论文
共 42 条
  • [31] Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial
    Parkes, G.
    Ungaro, R.
    Danese, S.
    Abreu, M.
    Arenson, E.
    Zhou, W.
    Ilo, D.
    Laroux, F. S.
    Deng, H.
    Gonzalez, Y. Sanchez
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I476 - I477
  • [32] Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: Results from the Phase 3 U-ACHIEVE maintenance trial
    Parkes, G.
    Ungaro, R.
    Danese, S.
    Abreu, M.
    Arenson, E.
    Zhou, W.
    Ilo, D.
    Laroux, S.
    Deng, H.
    Gonzalez, Y. S.
    Peyrin-Biroulet, L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 157 - 157
  • [33] Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial
    Parkes, G.
    Ungaro, R.
    Danese, S.
    Abreu, M.
    Arenson, E.
    Zhou, W.
    Ilo, D.
    Laroux, F. S.
    Deng, H.
    Gonzalez, Y. Sanchez
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I476 - I477
  • [34] CORRELATION OF HISTOLOGICAL ASSESSMENT OF MUCOSAL HEALING WITH LONG-TERM CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM PHASE 3 U-ACHIEVE MAINTENANCE TRIAL
    Parke, Gareth
    Ungaro, Ryan C.
    Danese, Silvio
    Abreu, Maria T.
    Arenson, Ethan
    Zhou, Wen
    Ilo, Dapo
    Laroux, Stephen
    Deng, Huiwen
    Gonzalez, Yuri Sanchez
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2022, 162 (07) : S970 - S970
  • [35] Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance Trials
    Sandborn, William
    Colombel, Jean-Frederic
    Feagan, Brian
    Marano, Colleen
    Strauss, Richard
    Han, Chenglong
    Gathany, Timothy
    Johanns, Jewel
    Zhang, Hongyan
    Gibson, Peter
    Collins, Judith
    Jarnerot, Gunnar
    Rutgeerts, Paul
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S519 - S519
  • [36] EARLY PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES WITH ABT-494 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE OR TUMOR NECROSIS FACTOR INHIBITORS: POST-HOC ANALYSIS OF PHASE 2 RANDOMIZED CONTROLLED TRIALS
    Strand, V.
    Tundia, N.
    Song, I. H.
    Meerwein, S.
    Lin, J.
    Chen, N.
    Friedman, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 855 - 855
  • [37] Early disease efficacy of guselkumab therapy in biologic-naive patients with moderately to severely active Crohn's disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies
    Afzali, A.
    Rubin, D. T.
    Danese, S.
    Rayyan, Y.
    Chen, M.
    Terry, N. A.
    Salese, L.
    Van Rampelbergh, R.
    Yee, J.
    Gomez, M.
    Wan, K. Y. Y.
    Yang, Z.
    Sands, B. E.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i200 - i201
  • [38] Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn's Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study
    D'Haens, G.
    Baert, F.
    Danese, S.
    Kobayashi, T.
    Loftus, E. V., Jr.
    Sandborn, W. J.
    Dornic, Q.
    Lindner, D.
    Kisfalvi, K.
    Marins, E. G.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S115 - S116
  • [39] Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Schrezenmeier, Hubert
    Kulasekararaj, Austin G.
    Mitchelli, Lindsay
    De Latour, Regis Peffault
    Devos, Timothy
    Okamoto, Shinichiro
    Wells, Richard
    Johnston, Karissa
    Popoff, Evan
    Cheung, Antoinette
    Wang, Jimmy
    Gustovic, Philippe
    Wang, Alice
    Tomazoz, Ioannis
    Patel, Yogesh
    Lee, Jong Wook
    BLOOD, 2021, 138
  • [40] Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
    Strand, Vibeke
    Kaeley, Gurjit
    Bergman, Martin
    Gladman, Dafna
    Coates, Laura
    Hur, Peter
    Kim, Nina
    Parikh, Bhumik
    Pertel, Patricia
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345